Beyond Zero: Understanding NEDA in Multiple Sclerosis and What It Means for You
"Is 'no evidence of disease activity' (NEDA) the ultimate goal in managing multiple sclerosis? Explore what NEDA means for pwMS and how it's reshaping treatment approaches."
The landscape of multiple sclerosis (MS) treatment has undergone a monumental transformation in recent years. What was once a relentless and often debilitating condition is now being approached with strategies aimed not just at slowing progression, but at achieving a state of "no evidence of disease activity," or NEDA. This paradigm shift offers new hope and improved outcomes for people living with MS (pwMS).
Imagine a future where MS doesn't dictate your daily life – where relapses are minimal, disability progression is halted, and brain scans show no new signs of disease. This is the promise of NEDA. But what exactly does NEDA entail, and how can it be achieved? Understanding NEDA is crucial for anyone affected by MS, as it empowers patients and their families to actively participate in treatment decisions and strive for the best possible quality of life.
This article breaks down the concept of NEDA in MS, explaining each component in plain language and highlighting the latest advancements in achieving this ambitious goal. We'll explore the role of various treatments, the importance of monitoring, and the challenges that remain, providing a comprehensive overview of NEDA and its potential impact on the lives of pwMS.
What NEDA Measures
NEDA is increasingly used to evaluate disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS). NEDA-3 means no relapses, no new disease activity on brain MRI, and no disability progression. NEDA-4 adds the absence of brain atrophy to those three criteria. These sources describe NEDA as an outcome measure in treatment assessment, but do not provide a prevalence figure in the supplied material.
How NEDA Became a Treatment Target
A 2017 commentary on NEDA says that neurologists may be misinformed about the concept’s provenance and may not accept it as a valid treatment target. The commentary set out to describe the brief history of NEDA and how it came to be adopted by the MS community. The supplied historical sources on MS more broadly discuss its discovery, early documented cases, treatments, and milestones, but their snippets do not specify those details.
Decoding NEDA: What Does 'No Evidence of Disease Activity' Really Mean?
NEDA isn't just a single measure; it's a composite outcome that considers several key aspects of MS. Achieving NEDA means meeting specific criteria across clinical and radiological assessments. Here's a breakdown of the core components:
- No Clinical Relapses: This means experiencing no new MS symptoms or worsening of existing symptoms that last for more than 24 hours. Relapses can significantly impact quality of life and contribute to long-term disability.
- No Disability Progression: Disability progression is typically measured using the Expanded Disability Status Scale (EDSS). NEDA requires that a patient's EDSS score remains stable, indicating that the disease isn't causing further physical impairment.
- No New MRI Activity: Magnetic resonance imaging (MRI) plays a crucial role in monitoring MS disease activity. NEDA requires the absence of new or enlarging lesions on brain or spinal cord MRI scans. These lesions represent areas of inflammation and damage in the central nervous system.
Cladribine and NEDA
A narrative review of cladribine tablets in relapsing-remitting MS reports that a treatment course given over two years provided protection against relapse, supporting the hypothesis that cladribine tablets have characteristics of an immune reconstitution therapy (IRT). The review describes CLARITY as evaluating cladribine tablets at cumulative doses of 3.5 mg/kg and 5.25 mg/kg over two years. The supplied material does not report a specific NEDA outcome for these doses. The other listed sources provide general MS research coverage or describe NEDA-3 as no clinical relapses, disability progression, or radiological activity.
Limits of NEDA-4 as a Predictor
NEDA-4 has been proposed as a treatment target for DMTs in RRMS, but its ability to distinguish long-term outcomes in MS remains uncertain. A systematic review and meta-analysis was conducted to assess its association with long-term disability outcomes and compare its performance with NEDA-3. The supplied summary does not state the review’s results, so it does not establish that NEDA-4 predicts long-term outcomes better than NEDA-3. NEDA-3 is a composite measure of relapses, disability progression, and radiological activity.
Comparing NEDA and MEDA
NEDA aims for the complete absence of clinical and radiological disease activity, and the 2026 source describes this target as very strict and difficult to sustain. The same source says that minimal evidence of disease activity (MEDA) was proposed as a more realistic goal that allows minimal disease activity. A separate study set out to compare natalizumab and fingolimod on NEDA-3 among people with RRMS over follow-up longer than two years. The supplied snippet does not include that study’s comparative results.
Looking Ahead: The Future of NEDA in MS Care
While NEDA represents a significant advancement in MS treatment, challenges remain. Accurately assessing and monitoring disease activity requires regular MRI scans and neurological evaluations, which can be burdensome for patients. Additionally, the definition of NEDA can vary slightly between different studies and clinical settings. Despite these challenges, the pursuit of NEDA is driving innovation in MS treatment and leading to better outcomes for pwMS. As research continues and new therapies emerge, the goal of achieving and sustaining NEDA will become increasingly attainable, offering hope for a future where MS has minimal impact on daily life.
NEDA as a Treatment Goal
The supplied article description presents NEDA as a significant shift in treatment goals for people living with MS. It says the article explains NEDA’s components, benefits, and strategies for pursuing the goal, aiming to provide patients and families with a clear roadmap. The source material does not give further details about systemic challenges or specific strategies.
NEDA in Real-World Care
NEDA-3 comprises freedom from clinical disease progression and relapses, as well as inflammatory MRI activity. A 2019 study notes that NEDA data had mainly come from post-hoc analyses of drug-approval studies, while less was known about its significance in real-world clinical settings. Another listed study assessed 24-month real-world effectiveness and safety of ofatumumab in RRMS, comparing treatment-naïve and previously treated patients and exploring predictors of failure to achieve NEDA-3. The supplied summary does not provide its findings.